JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (3): 77-80.doi: 10.6040/j.issn.1671-7554.0.2015.929

Previous Articles     Next Articles

Relationship between mir-99a expression and prognosis of epithelial ovarian cancer

XU Zhihong1, WU Xiaohua2, YAO Tiezhu3, WANG Xiaoxiang1, DUAN Xiaoyang1, SHI Jian1   

  1. 1. Department of Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China;
    2. Department of Obstetrics and Gynaecology, Bethune International Peace Hospital, Shijiazhuang 050000, Hebei, China;
    3. Department of Cardiology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China
  • Received:2015-09-28 Online:2016-03-10 Published:2016-03-10

PDF (PC)

236

Abstract: Objective To investigate the mir-99a expression in epithelial ovarian cancer(EOC), and its relationship with the clinicopathological features and prognosis. Methods The mir-99a expression in 137 cases of EOC tissues was detected with qRT-PCR assay. The correlation between mir-99a expression and clinicopathological features of EOC were analyzed. Survival curves for patients with different mir-99a expressions were plotted using the Kaplan-Meier method and compared using the log-rank test. Results The mir-99a expression reduced significantly in EOC tissues compared with that in adjacent normal tissues(P<0.001). Low mir-99a expression was significantly correlated with higher histological grade(P=0.027), lymph node metastasis(P=0.001), peritoneal metastasis(P<0.001), and higher FIGO stage(P<0.001). Kaplan-Meier analysis with log-rank test revealed that low mir-99a expression was correlated with short survival time of patients with EOC(log-rank test, P=0.005). Multivariate analysis showed that mir-99a expression was an independent prognostic factor for the overall survival(HR: 2.368, 95%CI: 1.621-10.925, P=0.016). Conclusion The mir-99a expression is an independent prognostic factor of patients with EOC. It can serve as a diagnostic and prognostic marker in clinical practice.

Key words: Epithelial ovarian cancer, Prognosis, mir-99a, Clinical pathology

CLC Number: 

  • R737.31
[1] Karimi-Zarchi M, Mortazavizadeh SM, Bashardust N, et al. The clinicopathologic characteristics and 5-year survival rate of epithelial ovarian cancer in Yazd, Iran[J]. Electron Physician, 2015, 7(6): 1399-1406. doi: 10.14661/1399. eCollection 2015.
[2] Cheng W, Liu J, Yoshida H, et al. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract[J]. Nature medicine, 2005, 11(5): 531-537.
[3] Saad AF, Hu W, Sood AK. Microenvironment and pathogenesis of epithelial ovarian cancer[J]. Hormones Cancer, 2010, 1(6): 277-290.
[4] Jönsson JM, Skovbjerg Arildsen N, Malander S, et al. Sex steroid hormone receptor expression affects ovarian cancer survival[J]. Transl Oncol, 2015, 8(5): 424-433.
[5] Jiang H, Qu L, Wang Y, et al. miR-99a promotes proliferation targeting FGFR3 in human epithelial ovarian cancer cells[J]. Biomedicine Pharmacotherapy, 2014, 68(2): 163-169.
[6] Farazi TA, Spitzer JI, Morozov P, et al. miRNAs in human cancer[J]. J Pathol, 2011, 223(2): 102-115.
[7] Bushati N, Cohen SM. microRNA functions[J]. Annu Rev Cell Dev Biol, 2007, 23:175-205.
[8] Calin GA, Croce CM. MicroRNA signatures in human cancers[J]. Nature reviews Cancer, 2006, 6(11): 857-866.
[9] 何玲, 林功标, 程金妹. MicroRNA在头颈肿瘤的研究进展[J]. 中华耳鼻咽喉头颈外科杂志, 2010, 2: 170-173.
[10] Tricoli JV, Jacobson JW. MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis[J]. Cancer Res, 2007, 67(10): 4553-4555.
[11] Croce CM, Calin GA. miRNAs, cancer, and stem cell division[J]. Cell, 2005, 122(1): 6-7.
[12] Ahmed FE, Jeffries CD, Vos PW, et al. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue[J]. Cancer Genomics Proteomics, 2009, 6(5): 281-295.
[13] Faruq O, Vecchione A. microRNA: Diagnostic Perspective[J]. Front Med, 2015, 2: 51. doi: 10.3389/fmed.2015.00051. eCollection 2015.
[14] Chen Z, Jin Y, Yu D, et al. Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma[J]. Oral Oncol, 2012, 48(8): 686-691.
[15] Li D, Liu X, Lin L, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma[J]. J Biol Chem, 2011, 286(42): 36677-36685.
[16] Sun D, Lee YS, Malhotra A, et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation[J]. Cancer Res, 2011, 71(4): 1313-1324.
[17] Catto JW, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer[J]. Cancer Res, 2009, 69(21): 8472-8481.
[18] Torres A, Torres K, Pesci A, et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma[J]. BMC Cancer, 2012, 12: 369. doi: 10.1186/1471-2407-12-369
[19] Sun J, Chen Z, Tan X, et al. MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma[J]. Med Oncol, 2013, 30(1): 411. doi: 10.1007/s12032-012-0411-9. Epub 2013 Jan 5.
[20] Cui L, Zhou H, Zhao H, et al. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma[J]. BMC Cancer, 2012, 12: 546. doi: 10.1186/1471-2407-12-546.
[1] LI Yinglin, SONG Daoqing, XU Zhonghua. Identification of FKBP11 expression in clear cell renal cell carcinoma using bioinformatics analysis [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 45-51.
[2] SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 47-52.
[3] LI Xingkai, LIU Zhanye, JIANG Yunfeng, LI Jun. Clinicopathological factors and prognosis between primary central and peripheral lung squamous cell carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 73-78.
[4] ZONG Shuai, XIAO Dongjie, LIU Hua, JIA Yanfei, MA Xiaoli, LI Huanjie, LI Ping, ZHENG Yan, WANG Yunshan. Expression of CSN5 and its correlation with the prognosis of gastric carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 12-16.
[5] SUN Qijing, CHEN Fangfang, LI Chunxiao, ZHANG Caiqing. Clinical value of PNI and HGB in evaluating the prognosis of the middle to late stage non-small cell lung cancer patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 55-59.
[6] LIN Jiaxiang, GUO Zijia, SU Peng, WANG Xiao, GUO Yaxin, WU Xiaojuan, XIANG Lei, ZHOU Zhiqiang, WANG Yan, CUI Xiujie, PAN Aifeng, GUO Chenghao. The role of CIP2A in the transformation of breast ductal epithelium and prognosis of invasive breast cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 100-106.
[7] ZHOU Lanlan, PAN Xueyi, GUO Yu. Clinical characteristics and prognosis of 48 patients with mixed phenotype acute leukemia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 79-83.
[8] ZHANG Xiying, ZHAI Chunyan, LI Jingsong, HAN Bo. Expression of EZH2 in Chinese Ewing sarcoma patients and its relationship with clinicopathological parameters and prognosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 84-91.
[9] LIU Huiling, WANG Xingwen, FENG Shaobin, FENG Hong, HAN Junqing. Association between high expression of scavenger receptor class B type I and the prognosis of colon cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 84-89.
[10] LI Xiaoning, CUI Lianqun. Treatment timing of non-infarct-related artery in patients with multi-vessel disease and acute myocardial infarction [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 50-54.
[11] WANG Wen, LIU Yao, LONG Fei, MA Weixia, SU Lili. Correlation between lymphocyte-to-monocyte ratio in peripheral blood and prognosis of malignant pleural mesothelioma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 72-77.
[12] LIU Tong, ZHANG Xin, WANG Chuanxin. Significance of IRX5 mRNA in the diagnosis and prognosis of colorectal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 69-74.
[13] MA Lin, ZHANG Dong, TANG Lei, YE Siyuan, YAN Chuanzhu, CAO Lili. Prognostic hematological biomarkers of amyotrophic lateral sclerosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(4): 46-50.
[14] QU Lixin, SHI Xinghua, DU Yifeng. Relationship between circulating platelets microparticles and endothelial microparticls and prognosis in patients with acute ischemic stroke [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(12): 32-36.
[15] LIU Xiao, LIU Zhiguang, FAN Zhisong, WANG Yuan, YANG Xingxiao, KONG Jieyu, CHEN Junzhuo, LIU Junxia. Prognostic analysis of patients with severe sepsis and septic shock [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(10): 80-84.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd